Safety and Efficacy Study of Topical Methyaminlevulinate (MAL) in Subjects With Facial Acne

Inclusion Criteria: * Subject willing to use an adequate contraceptive method or is surgically sterile, post menopausal, abstinent or with a same-sex partner. Adequate means of contraception include; IUD in use 30 days prior to day 0, barrier methods and spermicide in use atleast 14 days prior to day 0 or oral contraceptive in use for at least 6 months prior to day 0 * Age 18 or older * Capable of giving informed consent * Diagnosis of acne vulgaris on the face with at least 10 inflammatory lesions on both sides of the face at screening and day 0 * Global acne severity assessment score ≥ 3 at the screening and day 0 visit. Exclusion Criteria: * Allergy to methylaminolevulinate or any component of the vehicle * Acne fulminans or conglobata on the face * Clinical significant sensitivity to visible light, porphyria or porphyrin sensitivity * Use of any topical treatment for acne on the face within the previous 2 weeks before day 0 * Any use of systemic antibiotics within 1 month prior to day 0 or use of isotretinoin within 1 year prior to Day 0 * Exposure to ultraviolet radiation (UVB phototherapy, sun tanning salons) within 4 weeks of Day 0 * Use of any investigational drug within 4 weeks of Day 0 * Alcoholism or drug abuse in the past year * Any unstable or serious medical condition at the discretion of the investigator * Current pregnancy or lactation * Use of hormonal contraceptives solely for control of acne * Current use of oral contraceptives (unless subject is on a stable dose e.i. at least six months of treatment prior Day 0), testosterone or any other systemic hormonal treatment * Any serious dermatological disorder, including malignancies that would either put the subject at risk or interfere with efficacy or safety evaluations * Fitzpatrick phototype V or VI (inadequate penetration of red light in dark skin subjects) * Subjects with extensive facial hair (e.g. beard) that would either impair red light exposure or interfere with lesion evaluation.